南宫NG·28

关于我们
研发服务
服务平台
客户中心
新闻资讯
投资者关系
人力资源
EN
×
EN

  • 业务咨询

    中国：

    Email: marketing@hbyfcc.com

    业务咨询专线：400-780-8018

    （仅限服务咨询，其他事宜请拨打川沙总部电话）

    川沙总部电话: +86 (21) 5859-1500

    海外：

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com
在线留言×
点击切换
Customer Center
客户中心
Jun 28,2023
SAHA可有效恢复阿尔茨海默病模型的记忆能力，本研究中SAHA通过南宫NG·28合成
SAHA was synthesized by Medicilon and was given to mice as 50 mg/kg doses. Injections (10 mL/kg) were given intraperitoneally and were alternated daily between left and right sides of the abdomen. Chronic treatments of SAHA completely restored performance deficits in APP/PS1 mice.
查看更多
SAHA可有效恢复阿尔茨海默病模型的记忆能力，本研究中SAHA通过南宫NG·28合成
Jun 28,2023
TAK-243是一种有效的泛素激活酶小分子抑制剂，具有体内抗肿瘤功效，通过南宫NG·28使用HCC70模型进行
TAK-243 is a potent, mechanism-based small-molecule inhibitor of the ubiquitin activating enzyme (UAE), the primary mammalian E1 enzyme that regulates the ubiquitin conjugation cascade. TAK-243 has UAE-specific antitumor efficacy in vivo. Medicilon performed the experiment using the HCC70 (triple-negative breast cancer) model.
查看更多
TAK-243是一种有效的泛素激活酶小分子抑制剂，具有体内抗肿瘤功效，通过南宫NG·28使用HCC70模型进行
Jun 28,2023
法尼基转移酶抑制剂LNK-754单次口服后即可快速穿过血脑屏障，PK分析通过南宫NG·28进行
Pharmacokinetic studies revealed that after a single oral dose, the FTI (LNK-754) was cleared from plasma within 20 hours and could rapidly cross the blood-brain-barrier. Pharmacokinetic analysis was performed as a service provided by Medicilon.
查看更多
法尼基转移酶抑制剂LNK-754单次口服后即可快速穿过血脑屏障，PK分析通过南宫NG·28进行
Jun 28,2023
WYC-209可抑制恶性小鼠黑色素瘤肿瘤再生细胞增殖，SPR分析通过南宫NG·28使用Biacore 8K设备进行
The binding assay by surface plasmon resonance (SPR) analysis shows that WYC-209A and WYC-209B acid bind to RARs at nano-molar doses. SPR was carried out by Medicilon, using the Biacore 8K equipment.
查看更多
WYC-209可抑制恶性小鼠黑色素瘤肿瘤再生细胞增殖，SPR分析通过南宫NG·28使用Biacore 8K设备进行
Jun 28,2023
ARD-2128是一种PROTAC AR降解剂，具有出色的血浆和微粒体稳定性，体外稳定性和PK研究通过南宫NG·28进行
ARD-2128 has excellent plasma and microsomal stability in all the five species (Human, Mouse, Rat, Dog, and Monkey). The in vitro stability and pharmacokinetic (PK) studies were performed by Medicilon.
查看更多
ARD-2128是一种PROTAC AR降解剂，具有出色的血浆和微粒体稳定性，体外稳定性和PK研究通过南宫NG·28进行
Jun 28,2023
设计合成一系列DHODH抑制剂作为潜在的类风湿性关节炎治疗药物，PK研究通过南宫NG·28进行
Human dihydroorotate dehydrogenase (DHODH) is a viable target for the development of therapeutics to treat cancer and immunological diseases. Herein, researchers designed and synthesized a series of acrylamide-based novel DHODH inhibitors as potential rheumatoid arthritis (RA) treatment agents.
查看更多
设计合成一系列DHODH抑制剂作为潜在的类风湿性关节炎治疗药物，PK研究通过南宫NG·28进行
Jun 28,2023
开发并验证新的LC-MS/MS方法，用于定量人血浆中达拉非尼及其主要代谢物羟基达拉非尼 (OHD)。OHD（纯度>99%）通过南宫NG·28合成
OHD (purity >99 %) was synthesized by Medicilon. Medicilon synthetic chemistry team is capable of the independent design of synthesis pathways and complex compound treatments, key to helping accelerate drug discovery.
查看更多
开发并验证新的LC-MS/MS方法，用于定量人血浆中达拉非尼及其主要代谢物羟基达拉非尼 (OHD)。OHD（纯度>99%）通过南宫NG·28合成
Jun 28,2023
放射疗法用作肺癌的主要治疗方法，在次研究中建立抗电离辐射肺癌细胞系的放射治疗通过南宫NG·28进行
Radiation therapy is used as the primary treatment for lung cancer. In this study, radiation therapy for establish ionizing radiation-resistant lung cancer cell lines (A549-IR/H1299-IR) was supported by Medicilon.
查看更多
放射疗法用作肺癌的主要治疗方法，在次研究中建立抗电离辐射肺癌细胞系的放射治疗通过南宫NG·28进行
Jun 28,2023
CAR-T疗法主要针对白血病与恶性淋巴瘤，此研究中构建沉默PD-1的shRNA载体质粒，测序后质粒的鉴定通过南宫NG·28进行
Chimeric antigen receptor T cells (CAR-T) immunotherapy has shown promising clinical results in the treatment of leukemia and lymphoma, but the effectiveness is limited for solid tumors. The shRNA vector plasmid that silences PD-1 and preparation of CAR is constructed. The plasmids sequenced were fully identified by Medicilon.
查看更多
CAR-T疗法主要针对白血病与恶性淋巴瘤，此研究中构建沉默PD-1的shRNA载体质粒，测序后质粒的鉴定通过南宫NG·28进行
Jun 28,2023
索拉非尼的无定形固体分散体用于开发改良型口服生物利用度高的速释片剂，PK研究通过南宫NG·28进行
The SOR ASD tablets exhibited approximately 50% higher relative bioavailability in dogs than the marketed SOR tablet product, Nexavar®. The pharmacokinetic (PK) study of SOR ASD tablets and Nexavar® tablets was performed by Medicilon.
查看更多
索拉非尼的无定形固体分散体用于开发改良型口服生物利用度高的速释片剂，PK研究通过南宫NG·28进行
×
搜索验证
点击切换
友情链接: